Dermira, Inc. (DERM) financial statements (2020 and earlier)

Company profile

Business Address 275 MIDDLEFIELD ROAD
MENLO PARK, CA 94025
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 31355125221597
Cash and cash equivalents 1052964210755
Short-term investments 20825521010742
Receivables  021 7
Inventory, net of allowances, customer advances and progress billings 8    
Inventory 8    
Other undisclosed current assets 1461131
Total current assets: 335557284217105
Noncurrent Assets
Property, plant and equipment 11100
Long-term investments and receivables 3 25166
Long-term investments 3 25166
Intangible assets, net (including goodwill) 22224
Goodwill 11111
Intangible assets, net (excluding goodwill) 11114
Restricted cash and investments 1    
Other noncurrent assets 21112
Total noncurrent assets: 9429573
TOTAL ASSETS: 344561313222178
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 3940312614
Accounts payable 16151496
Accrued liabilities 232517176
Employee-related liabilities     2
Deferred revenue and credits54  
Other undisclosed current liabilities  60  (2)
Total current liabilities: 39105352612
Noncurrent Liabilities
Long-term debt and lease obligation 33279  2
Long-term debt, excluding current maturities 33279  2
Liabilities, other than long-term debt 126301111
Deferred revenue and credits25301010
Deferred tax liabilities, net 0001
Other liabilities 1100 
Other undisclosed noncurrent liabilities 281    
Total noncurrent liabilities: 315306301113
Total liabilities: 353411653625
Stockholders' equity
Stockholders' equity attributable to parent (9)150247185154
Common stock 00000
Additional paid in capital 736703498347236
Accumulated other comprehensive loss (0)(0)(0)(0)(0)
Accumulated deficit (745)(553)(250)(161)(83)
Total stockholders' equity: (9)150247185154
TOTAL LIABILITIES AND EQUITY: 344561313222178

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 4252377
Revenue, net523 7
Cost of revenue
(Cost of Goods and Services Sold)
 (1)    
Gross profit: 4152377
Operating expenses (256)(305)(113)(87)(39)
Other undisclosed operating income 1    
Operating loss: (214)(300)(91)(80)(32)
Nonoperating income 85   
Interest and debt expense (16)(8) (0)(0)
Loss from continuing operations before equity method investments, income taxes: (222)(303)(91)(80)(32)
Other undisclosed income from continuing operations before income taxes   210
Loss from continuing operations before income taxes: (222)(303)(89)(79)(32)
Income tax expense (benefit) 0  1(0)
Net loss available to common stockholders, diluted: (222)(303)(89)(78)(32)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (222)(303)(89)(78)(32)
Comprehensive loss: (222)(303)(89)(78)(32)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 00(0)0(0)
Comprehensive loss, net of tax, attributable to parent: (221)(303)(89)(78)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: